+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-10-30Number of Pages: 84

Preimplantation Genetic Diagnosis Market (Test Type - PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Preimplantation genetic diagnosis (PGD) is an adjuvant technique to in vitro fertilization (IVF) for detecting genetic diseases or conditions before the implantation of embryo. PGD can be performed for screening of a range of medical conditions such as Down’s syndrome, inheritable diseases and traits of other physiological abnormality. Increasing patient awareness about PGD technique and rising prevalence of genetic disorders among infants has led to the rise in demand for PGD along with IVF procedure. The combination of PGD and IVF  has improved the rate of successful pregnancy due to reduced chances of passing the undesired genetic material in the embryo.

The use of array comparative genomic hybridization (aCGH) and fluorescent in situ hybridization (FISH) techniques in PGD has improved the process efficiency and success rate of pregnancy through IVF. Demand for PGD, however, is dependent on the regulations governing infertility procedures in various countries. PGD for gender selection and HLA typing is banned in most parts of Asia, whereas it is regulated in the U.S. and in some parts of the European Union. Regulatory impact plays a major role in analyzing the global preimplantation genetic diagnosis market.

Based on the type of test, the global preimplantation genetic diagnosis market has been categorized into six segments: PGD for chromosomal aberrations, PGD for aneuploidy screening, PGD for gender selection, PGD for single gene disorder, PDG for HLA typing and PGD for X-linked diseases. PGD for aneuploidy screening held the highest share in 2013 as aneuploidy could lead to severe abnormalities. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. . Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated. However, this drawback is efficiently overcome by opting for preimplantation genetic diagnosis, since genetic screening for aneuploidy is performed before the embryo is implanted and pregnancy is conceived.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Each geographical market has been further analyzed based on the types of test. Europe dominated the global preimplantation genetic diagnosis market in 2013 due to increasing patient awareness and high number of IVF cycles being performed in the region. Conversely, North America is expected to grow at a higher CAGR during the forecast period due to rapid increase in the number of IVF cycles being performed and the rising disability rate due to increase in smoking. Moreover, high cost of the gender selection procedure and rising demand for identifying and selecting the gender by mothers increases the market share of PGD in gender selection. Restrictions on gender selection and detection of X-linked diseases in developing regions such as Asia Pacific, Latin America and Africa restrain the growth of the PGD market. Moreover, lack of patient awareness and inadequate healthcare facilities in the developing economies of these regions limit the use of PGD in HLA typing and detection of single gene disorder.

The global preimplantation genetic diagnosis market is characterized by the presence of some of the major companies including Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute. Market players are in constant endeavor to improve their technologies in genetic testing in order to enhance the efficiency and provide better services to healthcare practitioners.

preimplantation-genetic-diagnosis-market


Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. 

This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market.  

The market overview section explains market dynamics such as drivers, restraints and opportunities that influence the current and future status of the preimplantation genetic diagnosis market. Impact factors such as market attractiveness analysis and regulatory framework of PGD in various countries has been included in this section in order to provide a thorough analysis of the overall competitive scenario of the global preimplantation genetic diagnosis market. The report covers competitive analysis, which includes heat map analysis by key market players. Through heat map analysis, the stakeholder would be able to identify the presence of players across various segments of the market. All these factors would help market players gain a thorough understanding of the overall competitive scenario. The market players can then decide upon the business strategies and plans to be implemented in order to strengthen their position in the global market.  

The global preimplantation genetic diagnosis market has been differentiated based on the types of tests and geographies. Based on the types of tests, the global preimplantation genetic diagnosis market has been segmented into six categories: PGD for chromosomal aberrations, aneuploidy screening, X-linked diseases, single gene disorder, HLA typing and gender selection. A detailed market analysis of the segments mentioned above has been provided at the global level in this study. The market analysis is based on market size and forecast in terms of USD million for the period 2013 to 2020 along with the compounded annual growth rate (CAGR %) for the period 2014 to 2020, considering 2013 as the base year.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). This section further provides market size and forecast for various types of PFD tests in each region. The market size and forecast of the regional markets is provided for the period 2012 to 2020. CAGR (%) for each region is also estimated for the period 2014 to 2020, considering 2013 as the base year. The report also includes strategic recommendations, which would help market players sustain and grow in the highly competitive market. These recommendations would also help new entrants establish a strong position in the global preimplantation genetic diagnosis market.

Company profiles section comprises key information such as company overview, financial overview, product portfolio, business strategies and recent developments about major players operating in the preimplantation genetic diagnosis market. Key players profiled in the report include Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute.

The global preimplantation genetic diagnosis market is segmented into the following categories:

Preimplantation Genetic Diagnosis Market, by Test Type
  • PGD for Chromosomal Aberrations
  • PGD for Aneuploidy Screening
  • PGD for Gender Selection
  • PGD for Single Gene Disorder
  • PDG for HLA Typing
  • PGD for X-linked Diseases
Preimplantation Genetic Diagnosis Market, by Geography
  • North America
    • PGD for Chromosomal Aberrations
    • PGD for Aneuploidy Screening
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases
  • Europe
    • PGD for Chromosomal Aberration
    • PGD for Aneuploidy Screening
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases
  • Asia Pacific
    • PGD for Chromosomal Aberrations
    • PGD for Aneuploidy Screening
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases
  • Rest of the World (RoW)
    • PGD for Chromosomal Aberrations
    • PGD for Aneuploidy Screenin
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases



 
 
Back To Top